The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
PARticipation in inflammation
Open accessAbstract
In this issue of the JCI, Ferrell and colleagues report that mice lacking the proteinase-activated receptor-2 (PAR-2) were protected against a form of adjuvant-induced arthritis (1). Herein we discuss protease-activated receptors, their mechanism of activation, and the contexts in which they are thought to function. A useful unifying hypothesis emerges: protease-activated receptors link tissue injury to appropriate cellular responses, and such responses, while normally homeostatic, may contribute to disease. Protease-activated receptor-1 (PAR-1), the prototypical PAR, was identified in a search for the receptors that mediate the activation of platelets and other cells by the coagulation protease thrombin. Known to be a seven transmembrane domain G-protein–coupled receptor, PAR-1 is activated by proteolysis (Figure (Figure1).1). Thrombin binds to PAR-1’s N-terminal exodomain and cleaves it after Arg41 to generate a new receptor N-terminus. The first six amino acids of this new N-terminus, SFLLRN, then serve as a tethered ligand that binds intramolecularly to the receptor’s heptahelical bundle to effect transmembrane signaling and G protein activation. Thus PARs are, in essence, peptide receptors that carry their own ligands, which lie hidden until revealed by receptor cleavage. The synthetic peptide SFLLRN, which mimics the PAR-1 tethered ligand, is a PAR-1 agonist and activates PAR-1 independent of thrombin and receptor cleavage. Such peptide agonists have provided a ready tool for probing the effects of PAR activation in vitro and in vivo. Figure 1 Mechanism of PAR-1 activation. The N-terminus of PAR-1, a seven transmembrane domain G protein–coupled receptor, contains a protease cleavage site that, once cleaved by thrombin, results in a new N-terminus. The new N-terminal sequence, SFLLRN, ... Four PARs are currently known (recent reviews include refs. 2–4). PAR-1, PAR-3, and PAR-4 can be activated by thrombin, and thrombin is almost certainly a physiological activator of these receptors in vivo. Several other proteases can cleave these receptors productively and may also contribute to their function in vivo. PAR-2 can be activated by multiple trypsin-like serine proteases including: trypsin itself, mast cell tryptase, neutrophil proteinase 3, tissue factor/factor VIIa/factor Xa, and membrane-tethered serine protease-1. However PAR-2 is not cleaved by thrombin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protease-activated receptors in inflammation, neuronal signaling and pain
Vergnolle, N., Wallace, J. L., Bunnett, N. W., & Hollenberg, M. D. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01634-5 · Cited by 369
Cited by
Protease-Activated Receptors: Contribution to Physiology and Disease
OSSOVSKAYA, V. S., & BUNNETT, N. W. (2004) · Physiological Reviews · doi:10.1152/physrev.00028.2003 · Cited by 1,078
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
COUGHLIN, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01377.x · Cited by 1,035
Self-citationNeutrophil serine proteases: specific regulators of inflammation
Pham, C. T. N. (2006) · Nature Reviews Immunology · doi:10.1038/nri1841 · Cited by 1,022
The cytoprotective protein C pathway
Mosnier, L. O., Zlokovic, B. V., & Griffin, J. H. (2007) · Blood · doi:10.1182/blood-2006-09-003004 · Cited by 754
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
McFadyen, J. D., Stevens, H., & Peter, K. (2020) · Circulation Research · doi:10.1161/circresaha.120.317447 · Cited by 592
Metadata
- Authors
- Coughlin, S. R., & Camerer, E.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-01-01
- Volume
- 111
- Issue
- 1
- Pages
- 25-27
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143007399
- Cited by
- 251
- References
- 1
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.